176 related articles for article (PubMed ID: 23460040)
21. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of cyproterone acetate in achieving castration and preventing luteinizing hormone releasing hormone analogue induced testosterone surge in patients with prostate cancer.
Appu S; Lawrentschuk N; Grills RJ; Neerhut G
J Urol; 2005 Jul; 174(1):140-2. PubMed ID: 15947599
[TBL] [Abstract][Full Text] [Related]
23. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
Fornara P; Jocham D
Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of switching therapy of luteinizing hormone-releasing hormone analogue for advanced prostate cancer.
Shen YC; Kang CH; Chiang PH
Kaohsiung J Med Sci; 2016 Nov; 32(11):567-571. PubMed ID: 27847099
[TBL] [Abstract][Full Text] [Related]
25. Testosterone suppression with a unique form of leuprorelin acetate as a solid biodegradable implant in patients with advanced prostate cancer: results from four trials and comparison with the traditional leuprorelin acetate microspheres formulation.
Solarić M; Bjartell A; Thyroff-Friesinger U; Meani D
Ther Adv Urol; 2017 Dec; 9(6):127-136. PubMed ID: 28588651
[TBL] [Abstract][Full Text] [Related]
26. Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide.
Shim M; Bang WJ; Oh CY; Lee YS; Cho JS
Investig Clin Urol; 2019 Jul; 60(4):244-250. PubMed ID: 31294133
[TBL] [Abstract][Full Text] [Related]
27. Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer.
Yu EY; Getzenberg RH; Coss CC; Gittelman MM; Keane T; Tutrone R; Belkoff L; Given R; Bass J; Chu F; Gambla M; Gaylis F; Bailen J; Hancock ML; Smith J; Dalton JT; Steiner MS
Eur Urol; 2015 Feb; 67(2):334-41. PubMed ID: 24968970
[TBL] [Abstract][Full Text] [Related]
28. Leuprorelin acetate in prostate cancer: a European update.
Persad R
Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
[TBL] [Abstract][Full Text] [Related]
29. Correlation Between Testosterone and PSA Kinetics in Metastatic Prostate Cancer Patients Treated With Diverse Chemical Castrations.
Reis LO; Denardi F; Faria EF; Silva ED
Am J Mens Health; 2015 Sep; 9(5):430-4. PubMed ID: 25294865
[TBL] [Abstract][Full Text] [Related]
30. Changes in serum levels of prostatic acid phosphatase and prostate specific antigen after luteinizing hormone-releasing hormone analogue administration in patients with metastatic prostatic cancer in relation to glandular differentiation.
Sasagawa I; Nakada T; Kubota Y; Sawamura T; Izumiya K
Int Urol Nephrol; 1995; 27(6):769-74. PubMed ID: 8725045
[TBL] [Abstract][Full Text] [Related]
31. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer.
Tomera K; Gleason D; Gittelman M; Moseley W; Zinner N; Murdoch M; Menon M; Campion M; Garnick MB
J Urol; 2001 May; 165(5):1585-9. PubMed ID: 11342922
[TBL] [Abstract][Full Text] [Related]
32. Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer.
Shore ND; Chu F; Moul J; Saltzstein D; Concepcion R; McLane JA; Atkinson S; Yang A; Crawford ED
BJU Int; 2017 Feb; 119(2):239-244. PubMed ID: 26991743
[TBL] [Abstract][Full Text] [Related]
33. A cost-utility analysis of degarelix in the treatment of advanced hormone-dependent prostate cancer in the United Kingdom.
Lee D; Porter J; Gladwell D; Brereton N; Nielsen SK
J Med Econ; 2014 Apr; 17(4):233-47. PubMed ID: 24568188
[TBL] [Abstract][Full Text] [Related]
34. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
35. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard(®)/Depo-Eligard(®)) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study.
Braeckman J; Michielsen D
Arch Med Sci; 2014 Jun; 10(3):477-83. PubMed ID: 25097577
[TBL] [Abstract][Full Text] [Related]
37. Are all gonadotrophin-releasing hormone agonists equivalent for the treatment of prostate cancer? A systematic review.
Bolton EM; Lynch T
BJU Int; 2018 Sep; 122(3):371-383. PubMed ID: 29438592
[TBL] [Abstract][Full Text] [Related]
38. Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
Hussain A; Dawson N; Amin P; Engstrom C; Dorsey B; Siegel E; Guo C
J Clin Oncol; 2005 Apr; 23(12):2789-96. PubMed ID: 15837994
[TBL] [Abstract][Full Text] [Related]
39. Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer.
Zou Y; Tang F; Talbert JC; Ng CM
PLoS One; 2020; 15(3):e0230571. PubMed ID: 32208461
[TBL] [Abstract][Full Text] [Related]
40. Response to degarelix after resistance to luteinizing hormone-releasing hormone agonist therapy for metastatic prostate cancer.
Raddin RS; Walko CM; Whang YE
Anticancer Drugs; 2011 Mar; 22(3):299-302. PubMed ID: 21360851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
